Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duvoglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 6/20 | 1.00 |
| ▸ | GLA known ✓ | P06280 | 4/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 4/20 | 1.00 |
| ▸ | MGAM | O43451 | 4/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 1.00 |
| ▸ | SI | P14410 | 3/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | LCT | P09848 | 2/20 | 1.00 |
| ▸ | GBA3 | Q9H227 | 2/20 | 1.00 |
| ▸ | MAN2B1 | O00754 | 1/20 | 1.00 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TREH | O43280 | 1/20 | 1.00 |
| ▸ | GANAB | Q14697 | 1/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duvoglustat SCHEMBL15896655 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL12636878 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL19628194 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL15896654 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL12017699 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Deoxymannojirimycin SCHEMBL3367857 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL24518227 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL4330678 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL2969 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL21104989 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220320-A1 | Method For Capturing And Purification Of Biologics | AMICUS THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-9987263-B2 | Methods for treatment of Fabry disease | AMICUS THERAPEUTICS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170042868-A1 | Methods for Treatment of Fabry Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-02-16 | — | — | US | disclosed |
| US-20150258081-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | CENTOGENE IP GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| WO-2010004269-A2 | STEREOSPECIFIC SYNTHESIS | DEXTRA LABORATORIES LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042868-A1 | Methods for Treatment of Fabry Disease | GAA, HSP90B1, GBA1 | GAA 1/4885GLA 17/4885FUCA1 118/4885 |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | GAA 268/4885GLA 1234/4885FUCA1 1506/4885 |
| US-20150258081-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | MAN2B1, CMA1, GBA1 | GAA 4/4885GLA 51/4885FUCA1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.